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Background: Iron-deficient erythropoiesis results in excess formation of zinc protoporphyrin (ZPP), which can be
measured instantly and at low assay cost using portable haematofluorometers. ZPP is used as a screening marker of
iron deficiency in individual pregnant women and children, but also to assess population iron status in combination
with haemoglobin concentration. We examined associations between ZPP and disorders that are common in Africa.
In addition, we assessed the diagnostic utility of ZPP (measured in whole blood and erythrocytes), alone or in
combination with haemoglobin concentration, in detecting iron deficiency (plasma ferritin concentration <15 μg/L).
Methods: Single blood samples were collected from a population sample of 470 rural Kenyan women with
singleton pregnancies, gestational age 13 to 23 weeks, and haemoglobin concentration ≥90 g/L. We used linear
regression analysis to assess associations between ZPP and iron markers (including anaemia), factors known or
suspected to be associated with iron status, inflammation markers (plasma concentrations of C-reactive protein and
α1-acid glycoprotein), infections (Plasmodium infection, HIV infection), and other disorders (α+-thalassaemia, plasma
concentrations of total bilirubin, and lactate dehydrogenase). Subsequently, in those without inflammation,
Plasmodium infection, or HIV infection, we used logistic discriminant analysis and examined receiver operating
characteristics curves with corresponding area-under-the-curve to assess diagnostic performance of ZPP, alone and
in combination with haemoglobin concentration.
Results: Individually, whole blood ZPP, erythrocyte ZPP, and erythrocyte protoporphyrin had limited ability to
discriminate between women with and without iron deficiency. Combining each of these markers with
haemoglobin concentration had no additional diagnostic value. Conventional cut off points for whole blood ZPP
(>70 μmol/mol haem) resulted in gross overestimates of the prevalence of iron deficiency.
Conclusions: Erythrocyte ZPP has limited value to rule out iron deficiency when used for screening in conditions
with a low prevalence (e.g., 10%). ZPP is of unreliable diagnostic utility when discriminating between pregnant
women with and without iron deficiency. Based on these findings, guidelines on the use of ZPP to assess iron
status in individuals or populations of pregnant women need review.
Trial registration: NCT01308112 (2 March 2011).
Keywords: Erythrocyte protoporphyrin, Iron deficiency, Kenya, Malaria, Plasmodium, Pregnancy, Zinc protoporphyrin* Correspondence: mart.mwangi@gmail.com
1Maseno University, School of Public Health and Community Development,
Private Bag, Maseno, Kenya
2Wageningen University, Cell Biology and Immunology Group, P.O. Box 338,
6700 AH Wageningen, The Netherlands
Full list of author information is available at the end of the article
? 2014 Mwangi et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Mwangi et al. BMC Medicine 2014, 12:229 Page 2 of 13
http://www.biomedcentral.com/1741-7015/12/229Background
Zinc protoporphyrin (ZPP) indicates the systemic supply
of iron to erythrocytes in bone marrow. Iron-deficient
erythropoiesis results in excess formation of ZPP, which
can be measured instantly and at low assay cost using
portable haematofluorometers. ZPP has been used as a
screening marker to manage iron deficiency in children
and pregnant women [1,2], with the reported advantage
that values remain stable throughout gestation in women
with adequate iron nutrition [3-5]. ZPP has also been re-
commended to be used in combination with haemoglo-
bin concentration in surveys to assess population iron
status [1,6]. We have concerns, however, about gross
discrepancies between reported prevalence estimates for
iron deficiency obtained by ZPP and circulating ferritin
concentrations [7,8].
ZPP is the predominant form of non-haem proto-
porphyrin in normal erythrocytes [2]. Non-haem proto-
porphyrin also includes free erythrocyte protoporphyrin
(FEP, i.e., the metal-free form that occurs naturally in
erythrocytes). If the supply of iron is insufficient or when
iron utilization is impaired (e.g., anaemia of chronic dis-
ease), zinc is used in the biosynthetic pathway of haem
instead of iron, resulting in iron-zinc substrate competi-
tion for ferrochelatase and the formation of ZPP. Thus,
increased ZPP concentrations in whole blood or erythro-
cytes reflect depleted iron stores and a decrease in circu-
lating iron in the bone marrow [1,2]. Contrary to haem,
ZPP and FEP fluoresce when exited at 408 nm (emis-
sion: 555 to 780 nm). Because the intensity of the fluor-
escent signal is proportional to the molar ratio of ZPP to
haemoglobin, haematofluorometer measurements should
theoretically not be influenced by the blood sample vol-
ume, pregnancy-induced haemodilution, or whether it is
determined in fresh whole blood or in erythrocytes. In
practice, however, measurement in washed erythrocytes
can yield more valid results because washing removes
haemoglobin breakdown products such as bilirubin or
other serum constituents (e.g., riboflavin) that fluoresce
in the same wavelength range as the porphyrins [9]. In
addition to being raised in iron deficiency, ZPP can be
elevated by other factors causing an inadequate supply
of iron to erythroblasts (inflammation), increased ery-
thropoiesis (haemolysis, sickle cell anaemia, thalassae-
mia), or disturbances in the haem synthetic pathway
(lead poisoning) [1].
In many disorders, the ratio of ZPP and FEP is highly
variable because of the high FEP content in reticulocytes.
Using acid extraction, chelated zinc can be liberated
from ZPP, yielding a larger pool of metal-free erythro-
cyte protoporphyrin (henceforth referred to as erythro-
cyte protoporphyrin, EP) [1].
We studied pregnant women with the aim to examine
associations between ZPP and disorders that are commonin Africa, namely Plasmodium infection, HIV infection,
and α+-thalassaemia. In addition, we assessed the diag-
nostic utility of ZPP (measured in whole blood and ery-
throcytes) and EP, either alone or in combination with
haemoglobin concentration, in detecting iron deficiency
defined as plasma ferritin <15 μg/L.
Methods
Study population
For this study, we used samples collected at baseline for a
randomised controlled trial to investigate the safety and ef-
ficacy of iron supplementation in Kenyan pregnant women.
The study (www.clinicaltrials.gov: NCT01308112) received
ethical clearance from review boards at the Kenyatta
National Hospital/University of Nairobi, Kenya, and
the London School of Hygiene and Tropical Medicine,
England; written informed consent was obtained from all
participating women. Field work was conducted from
October 2011 to October 2012 in a rural area highly
endemic for malaria in Nyanza Province, western
Kenya. We set up a surveillance system to detect preg-
nancies in the late stage of the first trimester to the
early stage of the second trimester. Pregnancy and ges-
tational age were confirmed and determined by urine
test and ultrasound examination, respectively. Immedi-
ately upon confirmation of pregnancy, women received
therapeutic courses of albendazole and praziquantel
against geohelminth infections and intestinal schisto-
somiasis, respectively.
At the second visit to the research clinic, 14 to 21
days after the initial visit, we collected a venous blood
sample (6 mL) to measure haemoglobin concentrations
(HemoCue301, ?ngelholm, Sweden) and ZPP in whole
blood and washed erythrocytes (both in duplicate; Aviv
206D, Lakewood NJ, USA). Erythrocytes were stored
in DNA-stabilizing buffer (AS1, Qiagen, Valencia, CA,
USA). To wash erythrocytes, blood samples were cen-
trifuged (8 min, 600 ? g), and plasma was removed and
replaced with an equal volume of phosphate buffered
saline (Medicago, Uppsala, Sweden; catalogue no. 09-
2051-100). Following renewed centrifugation (8 min,
600 ? g), the supernatant and buffy coat were discarded.
For the measurement of EP, washed erythrocytes (20 μL)
were transferred to 2 mL cryotubes prefilled with 0.3 mL
solution 0.9% saline and 50% Celite (Sigma-Aldrich, cata-
logue 525235, St. Louis, MO, USA). Aliquots were stored
in liquid nitrogen and dry ice until analysis for EP concen-
tration in the Netherlands.
Plasma was stored immediately after blood collection
and separation in liquid nitrogen ( ? 196?C) in the field,
and at ? 80?C during transport (May 2013) and subsequent
storage until analysis (July 2013) in the Netherlands. Un-
der these conditions, we believe that degradation of folate
or vitamin B12 in stored samples was negligible.
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sent had been obtained; they were likely to be available
for study until 1 month after delivery and planning to
deliver in the pre-designated health facility. Women were
excluded when having obvious mental retardation or a
metabolic disorder, a medical history of sickle cell an-
aemia, epilepsy, diabetes, an obstetric history suggestive of
eclampsia or pre-eclampsia, were carrying multiples, the
gestational age at the second visit was <13 weeks or
>23 weeks, no venous blood was collected, or haemoglo-
bin concentration was <90 g/L.
As per national guidelines, antenatal care visits should
be used to provide daily supplementation with iron and
folic acid, as well as intermittent preventive treatment
(IPT) with sulfadoxine-pyrimethamine against malaria.
However, our surveillance system captured women before
they would normally make their first antenatal care visit.
In our trial, we daily administered experimental supple-
ments with or without iron but commencing only after
blood collection; we did not supplement with folic acid
because of a lack of published evidence of haematological
benefits and because of concerns about reduced efficacy
of IPT with the antifolates sulphadoxine-pyrimethamine.
As part of the consent procedure, women were advised to
attend regular health services to receive antenatal care as
usual, including IPT and antiretroviral therapy, except that
they were instructed to not take supplements with iron
and/or folic acid supplied by these services or from other
sources. Thus, women were unlikely to have taken supple-
ments with iron or folic acid or at the time of blood col-
lection, although we cannot exclude the possibility that
some women had already received such supplements from
shops or other sources.
Laboratory analyses
ZPP content was measured with the AVIV ZPP haema-
tofluorometer, Model 206D (Aviv, Lakewood Township,
NJ, USA). Control samples at low, medium, and high
levels (AVIV) were run after every 30 readings, while
two level calibration (AVIV; low, high) samples were run
twice per year. Protoporphyrins were extracted and se-
parated from haem as described [10] and determined
quantitatively using an Edinburgh Instruments FLS900
fluorescence spectrometer and a protoporphyrin IX stan-
dard (Sigma-Aldrich, catalogue 282820).
We measured plasma iron markers (concentrations of
ferritin, soluble transferrin receptor, and transferrin),
plasma inflammation markers (concentrations of C-
reactive protein [CRP] and α1-acid glycoprotein [AGP]),
vitamins (plasma concentrations of folate and total vita-
min B12), and markers of haemolysis (plasma concen-
trations of lactate dehydrogenase and total bilirubin) on
a Beckman Coulter UniCel DxC 880i analyser as per
the manufacturer ? s instructions. For test descriptionsand analytic performance characteristics, we refer to
the manufacturer ? s website [11].
Plasmodium antigenaemia was assayed by dipstick tests
(Access Bio Inc., Somerset, NJ, USA; CareStart, catalogue
G0151 and G0171) that can detect P. falciparum-specific
histidine-rich protein-2 (HRP2), Plasmodium lactate de-
hydrogenase (pLDH) specific to either P. falciparum or to
non-falciparum species, i.e., P. ovale, P. malariae, or P.
vivax. Whereas HRP2-based tests detect current or recent
P. falciparum infection, pLDH-based tests only indicate
current infection [12-14]. HIV infection was assayed using
antibody tests (Alere, Waltham, MA, USA; confirmed by
Unigold, Trinity Biotech, Bray, Ireland, and/or Bioline,
Pantech, Umhlanga, South Africa).
We determined α+-thalassaemia genotype by polymer-
ase chain reaction [15,16]; for practical reasons, we
could perform this analysis only in the first 216 succes-
sively recruited women.
Definitions
In our analysis of the diagnostic performance of ZPP, we
defined iron deficiency as the absence or near-absence
of storage iron, indicated by plasma ferritin concentra-
tion <15 μg/L [17], in women without inflammation,
Plasmodium infection, or HIV infection. This is in ac-
cordance with the WHO ? s recommendation that popula-
tion iron status is measured by ferritin concentration
except where inflammation is prevalent [2].
Other definitions were as follows: anaemia: haemoglo-
bin concentration <110 g/L [18]; inflammation: plasma
concentrations of CRP >10 mg/L [19] and/or AGP >1 g/L
[20]; gravidity: the number of times a woman reported to
have been pregnant, regardless of the outcome of these
pregnancies, with twins and other multiple births counted
as 1, and including the current pregnancy; Plasmodium
infection was defined as any infection: one or more posi-
tive results for the presence of pLDH or HRP2 in plasma
(dipstick tests) or P. falciparum DNA (PCR test); current
or recent P. falciparum infection (similarly, but restricted
to results from dipstick tests); or P. falciparum infection
by PCR.
Statistical analysis
Data were analysed using SPSS version 22 (IBM, Armonk,
NY, USA). For ZPP, we used the mean of duplicate values;
the coefficients of variation for whole blood and ery-
throcytes were 2.9% and 5.2%, respectively. Data were
described as means (SDs), medians (25th and 75th per-
centiles), or prevalence values in the overall population
or in women without inflammation (plasma concentra-
tions CRP ≥10 mg/L or AGP ≥1.0 g/L), HIV infection,
or Plasmodium infection.
Univariate linear regression analysis was used to explore
associations between ZPP and iron markers (including
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with iron status (age, gestational age, gravidity, plasma
concentrations of folate and total vitamin B12), inflam-
mation markers, infections (Plasmodium infection, HIV
infection), and other disorders suspected to be associ-
ated with ZPP (α+-thalassaemia, plasma concentrations
of bilirubin and lactate dehydrogenase). In these ana-
lyses, ZPP values were normalised by log transforma-
tion; exponentiation of results yielded associations being
expressed as percentage differences. Multivariate linear re-
gression analysis with a backward elimination procedure
was used to derive a parsimonious model of factors that
were independently associated with ZPP. For whole blood
ZPP and erythrocyte ZPP, this resulted in different sets of
factors being included.
We assessed the diagnostic performance of ZPP (both
in whole blood and erythrocytes) in detecting iron defi-
ciency. Because plasma ferritin concentration reacts as
an acute phase protein, we restricted these analyses to
women without inflammation, Plasmodium infection, or
HIV infection.
Combinations of ZPP and haemoglobin concentration
may have better ability than single markers to distin-
guish between the presence and absence of iron deficiency.
Thus, we used scatter plots and logistic discriminant ana-
lysis to assess the diagnostic performance of ZPP com-
bined with haemoglobin concentration. Receiver operating
characteristics (ROC) curves were produced using the
probability of iron deficiency as a function of ZPP and
haemoglobin concentration as a quantitative test out-
come. Diagnostic performance was assessed by visual
inspection of these curves and by assessing differences
in the area-under-the-curve (AUC) with corresponding
P values. Similar analyses were performed for EP
concentration.
We subsequently assessed the diagnostic performance
of ZPP as a dichotomised variable, with various thresholds.
First, we used threshold values for ZPP of 70 μmol/mol
haem and 40 μmol/mol haem [1,2] depending on whether
the assay was conducted in whole blood or washed eryth-
rocytes. The whole blood ZPP value of 70 μmol/mol haem
[1,2,6] (2.7 μg/g haemoglobin) was derived from the 95%
upper limit of the reference values for women and
children participating in the US National Health and
Nutrition Examination Survey II, after excluding indi-
viduals with anaemia, low transferrin saturation, and
elevated blood lead concentrations. The cut-off point
for erythrocyte ZPP of 40 μmol/mol haem is based
on several small studies comparing iron-deficient and
iron-replete individuals [9,21].
Given a diagnostic test with a binary outcome, there
necessarily exists a set of paired values for sensitivity
and specificity that yields a prevalence estimate that is
identical to the true prevalence. Based on this premise, wedetermined ZPP cut-off points that would yield unbiased
estimates of the prevalence of iron deficiency, with true
values arbitrarily taken as 10%, 30%, and 50%. The me-
thods to determine sensitivity and specificity pairs from
the ROC curves, and thus these cut-off values for ZPP,
will be described elsewhere [22].
Results
Population characteristics
Plasmodium infection was highly prevalent but with low
activity, as judged by low plasma concentrations of
inflammation markers, lactate dehydrogenase and bili-
rubin (Table 1). One-fifth of women had HIV infection
and one-third had inflammation; they had poor iron
status, with 37% being anaemic, 53% being iron defi-
cient, and 27% being iron replete. Iron status was
uncertain in 20% of women because they had inflam-
mation with plasma ferritin concentrations in the nor-
mal range, which indicates either iron repletion or iron
deficiency with elevated ferritin concentrations due to
inflammation.
The prevalence of iron deficiency as defined by whole
blood ZPP >70 μmol/mol haem, erythrocyte ZPP >70
μmol/mol haem, and erythrocyte ZPP >40 μmol/mol
haem was 73.4%, 23.4%, and 46.4%, respectively. α+-thalas-
saemia was common, with 41% and 8% of women being
heterozygous and homozygous, respectively.
Factors associated with ZPP
Both in univariate analysis and in parsimonious models
obtained by multivariate analysis, whole blood and ery-
throcyte ZPP were associated with iron deficiency, an-
aemia, and plasma concentrations of soluble transferrin
receptor (Tables 2 and 3). For example, in univariate
analysis, each unit increment (1 mg/L) in plasma con-
centrations of soluble transferrin receptor was associated
with a 32% increase in whole blood ZPP. Although
whole blood ZPP seemed associated with gravidity and
gestational age in multivariate analysis, such associations
were not found in univariate analysis, or for erythrocyte
ZPP (Table 3). Both univariate and multivariate analysis
suggested that bilirubin concentration was associated
with reduced erythrocyte ZPP, but such associations
were not found in whole blood ZPP. Plasmodium infec-
tion was associated with ZPP, regardless of the case def-
inition for Plasmodium infection, whether assessed in
whole blood or erythrocytes, or whether examined by
univariate or multivariate analysis. There was no evi-
dence that inflammation was associated with ZPP other
than that plasma α1-acid glycoprotein concentration ap-
peared to be associated with elevated whole blood ZPP
in univariate analysis. We also found no evidence that
ZPP was associated with α+-thalassaemia genotype. In
univariate analysis, plasma vitamin B12 concentration was
Table 1 Characteristics of the populations studied
Characteristic All women Women without either inflammation,
Plasmodium infection, or HIV infection
n 470 175
Age
<20 years 20.6% (97) 17.1% (30)
≥20 years 79.4% (373) 82.9% (145)
Gestational age
13? 14 weeks 9.1% (43) 6.3% (11)
15? 16 weeks 25.7% (121) 25.1% (44)
17? 18 weeks 29.6% (139) 26.3% (46)
19? 21 weeks 24.5% (115) 30.3% (53)
22? 25 weeks 11.1% (52) 12.0% (21)
Gravidity
Primigravida 18.1% (85) 17.7% (31)
Secundigravida 19.6% (92) 16.0% (28)
Multigravida 62.3% (293) 66.3% (116)
Plasma CRP concentration, mg/L 4.3 [2.1? 10.4] 0
Plasma AGP concentration, g/L 0.72 [0.60 ? 0.93] 0
Inflammation
Plasma CRP concentration ≥10 mg/L 26.8% (126) 0
Plasma AGP concentration ≥1 g/L 18.1% (85) 0
Plasma concentrations of CRP ≥10 mg/L, or AGP ≥1.0 g/L 32.3% (152) 0
HIV infection 21.1% (99)a 0
Plasmodium infection
Any Plasmodium infection,b by dipstick or PCR 37.2% (175) 0
Current or recent P. falciparum infection, by either HRP2- or pLDH-based dipstick 19.5% (91) 0
P. falciparum, by PCR 34.7% (163) 0
Haemoglobin concentration, g/L 113.2 (11.4) 115.7 (10.8)
Anaemia (haemoglobin concentration <110 g/L) 37.2% (175) 25.7% (45)
Plasma ferritin concentration, μg/L 13.9 [8.2? 29.2] 10.6 [7.0? 18.5]
Iron status
Iron deficient (plasma ferritin concentration <15 μg/L) 52.8% (248) 64.6% (113)
Iron replete (plasma ferritin concentration ≥15 μg/L, without inflammation) 27.2% (128) 35.4% (62)
Uncertain (plasma ferritin concentration ≥15 μg/L, with inflammation) 20.0% (94) 0
Whole blood ZPP, μmol/mol haem 90 [68 ? 121] 87 [63? 121]
Whole blood ZPP >70 μmol/mol haem 73.4% (345) 69.1% (121)
Erythrocyte ZPP, μmol/mol haem 36 [20 ? 66] 42 [20? 74]
Erythrocyte ZPP >70 μmol/mol haem 23.4% (110) 28.6% (50)
Erythrocyte ZPP >40 μmol/mol haem 46.4% (218) 52.6% (92)
EP concentration, μg/L 203 [117? 428]a 224 [130? 476]c
Plasma sTfR concentration, mg/Ld 1.94 [1.48 ? 2.63] 1.87 [1.36? 2.62]
Plasma transferrin concentration, g/L 3.12 (0.56) 3.21 (0.54)
Plasma folate concentration, μg/Le 6.91 [5.45 ? 9.39]f 6.55 [5.21? 8.87]c
Plasma folate concentration <3 μg/L 0.6% (3/466)f 0.6% (1/174)c
Plasma vitamin B12 concentration, pmol/L
g 425 [311? 651]f 413 [307? 638]c
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Table 1 Characteristics of the populations studied (Continued)
Plasma vitamin B12 concentration <150 pmol/L 0.9% (4/466)
f 0.6% (1/174)c
Plasma bilirubin concentration, μmol/L 6.9 [4.9? 9.4]f 7.1 [4.8? 9.4]c
α+-thalassaemia genotype
Normal 51.2% [109/213]h 48.4% [44]i
Heterozygote 41.3% [88/213]f 42.9% [39]i
Homozygote 7.5% [16/213]f 8.8% [8]i
Values indicate mean (SD), median [25th and 75th percentile] or % (n).
AGP, α1-acid glycoprotein protein; CRP, C-reactive protein; EP, Erythrocyte protoporphyrin; HRP2, P. falciparum-specific histidine-rich protein-2; pLDH, Plasmodium-
specific lactate dehydrogenase; sTfR, Soluble transferrin receptor; ZPP:H, Zinc protoporphyrin:haem.
aMissing values resulted in n =468; bOnly one participant had infection by a Plasmodium species other than P. falciparum; cMissing values resulted in n =174; Reference
values d0.8 1.9 mg/L and e2.6 15.4 μg/L; fMissing values resulted in n =466; Reference values g130 700 pmol/L; Missing values resulted in hn =213 and in =91.
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peared in multivariate analysis. By contrast, there was no
evidence for an association between plasma folate concen-
tration and ZPP in univariate analysis, but in multivariate
analysis, it was associated with increased ZPP.
Diagnostic utility of ZPP
In the restricted population (i.e., women without inflam-
mation, Plasmodium infection, or HIV infection), whole
blood ZPP, erythrocyte ZPP, and EP concentration had
only modest ability to discriminate between women with
and without iron deficiency (Figure 1, panels A and B).
Erythrocyte ZPP scored the best out of these three mar-
kers, with an AUC of 0.73 (Figure 1, footnote). Haemo-
globin concentration also performed poorly when used
individually, and had no added diagnostic value when
used in combination with whole blood ZPP, erythrocyte
ZPP or EP concentration (Figure 1, panels C? H).
At a cut-off point of 70 μmol/mol haem, whole blood
ZPP had sensitivity and specificity of 78% and 47%, re-
spectively, of detecting iron deficiency (Table 4). This
low specificity results in low positive predictive values
(i.e., the probability of a test result correctly indicating
iron deficiency) and gross overestimates of the prevalence
of iron deficiency, particularly when the true prevalence is
low. For example, at a hypothetical prevalence of 10%, the
positive predictive value would be 14%, and the estimated
prevalence would be 56% (Table 4).
Erythrocyte ZPP >70 μmol/mol haem had much bet-
ter specificity (87%) but a low sensitivity (38%), whilst
values >40 μmol/mol haem yielded intermediate values
for sensitivity and specificity (64% and 68%, respectively;
values obtained from ROC curve analysis, Figure 1). With
our sensitivity and specificity values, unbiased estimates
for hypothetical prevalence values of 50%, 30%, or 10%
would be produced at whole blood ZPP cut-off points of
85 μmol/mol haem, 102 μmol/mol haem, and 160 μmol/
mol haem, respectively. Corresponding cut-off points for
erythrocyte ZPP would be 34 μmol/mol haem, 52 μmol/
mol haem, and 81 μmol/mol haem.Even at a sensitivity of 95%, as may be applied for
screening purposes, a negative test result obtained as
whole blood ZPP ≤49 μmol/mol haem would be insuffi-
cient to rule out iron deficiency, because negative predict-
ive values (i.e., the probability of a test result correctly
indicating absence of iron deficiency), would only be 39%,
60%, and 85% at prevalence values of 50%, 30%, or 10%,
respectively (Table 4).
At a prevalence of 19%, erythrocyte ZPP ≤11 μmol/mol
haem (corresponding to a sensitivity of 95%) would yield
97% probability of ruling out iron deficiency, resulting in
iron deficiency being excluded in 18% (=100%? 82%;
Table 4) of women. At higher prevalence values, this sen-
sitivity is insufficient to rule out iron deficiency as judged
by negative predictive values.
Discussion
In the population studied, both whole blood ZPP and
erythrocyte ZPP were mostly determined by iron markers
including anaemia, whilst inflammation, Plasmodium in-
fection, and HIV infection played only minor roles. When
used individually, whole blood ZPP, erythrocyte ZPP, and
EP had limited ability to discriminate between women
with and without iron deficiency, whilst combining each
of these markers with haemoglobin concentration had no
additional diagnostic value. This limited diagnostic value
was also apparent when using dichotomised variables for
whole blood ZPP and erythrocyte ZPP. Conventional cut-
off points for whole blood ZPP (>70 μmol/mol haem)
can result in gross estimates of the prevalence of iron
deficiency, particularly when the true prevalence is low.
Erythrocyte ZPP may have limited value to rule out
iron deficiency when used for screening in conditions
with a low prevalence (e.g., 10%).
Our study was designed to investigate the diagnostic
utility of ZPP in a malaria endemic, resource-poor set-
ting that has a high prevalence of α+-thalassaemia and
other haemoglobin disorders. This is particularly rele-
vant because the World Health Organization (WHO)
no longer recommends that children in malaria-endemic
Table 2 Factors associated with ZPP (μmol/mol haem) measured in whole blooda
Univariate analysis Multivariate analysisb
Δc (95% CI) P Δc (95% CI) P
Gravidity 0.68 0.04
Primigravida [Reference] [Reference]
Secundigravida ? 2.3% (? 15.6% to 13.1%) 0.5% (? 9.6% to 11.8%)
Multigravida 2.7% (? 8.9% to 15.7%) 9.4% (0.1% to 19.6%)
Gestational age 0.87 0.008
13? 14 weeks [Reference] [Reference]
15? 16 weeks 5.4% (? 11.3% to 25.3%) 6.7% (? 5.6% to 20.7%)
16? 18 weeks 6.1% (? 10.4% to 25.7%) ? 4.0% (? 14.9% to 8.3%)
19? 21 weeks 2.0% (? 14.3% to 21.3%) ? 7.3% (? 18.2% to 5.1%)
22? 25 weeks ? 1.0% (? 19.0% to 20.9%) ? 11.0% (? 23.0% to ? 2.8%)
Anaemia 64% (51.2% to 77.8%) <0.001 33.5% (23.9% to 43.9%) <0.001
Iron deficiencyd 26.3% (15.8% to 37.8%) <0.001 16.6% (9.1% to 24.6%) <0.001
Plasma sTfR concentration, mg/L 31.9% (28.1% to 35.9%) <0.001 24.5% (20.6% to 28.5%) <0.001
Plasma transferrin concentration, g/L 30.9% (21.4% to 41.2%) <0.001 ?
Plasma folate concentration, 10 μg/L 6.1% (? 7.2% to 21.4%) 0.39 12.8% (2.9% to 22.7%) 0.01
Plasma vitamin B12 concentration, 100 pmol/L ? 1.8% (? 3.4% to ? 0.2%) 0.03 ?
Plasma total bilirubin concentration, μmol/L 0.7% (? 0.4% to 1.8%) 0.20 ?
Plasma LDH concentration, 10 IU/L 1.5% (0.6% to 2.5%) 0.001 ?
α+-thalassaemia genotype 0.67
Normal [Reference] ?
Heterozygote ? 3.8% (? 16.1% to 10.2%) ?
Homozygote ? 10.0% (? 30.2% to 16.1%) ?
Plasmodium infection
Any Plasmodium spp., by any dipstick or PCR 8.0% (? 1.6% to 18.4%) 0.10 ?
Current or recent P. falciparum infectione 5.1% (? 6.2% to 17.8%) 0.39 ?
P. falciparum, by dipsticke or PCR 8.1% (? 1.4% to 18.6%) 0.10 ?
P. falciparum, by PCR 9.9% (0.1% to 20.7%) 0.05 ?
HIV infection 5.2% (? 14.9% to 6.2%) 0.37 ?
Plasma CRP concentration, mg/L 0.2% (? 0.1% to 0.5%) 0.27 ?
Plasma AGP concentration, g/L 21.5% (3.2% to 43.0%) 0.02 ?
Inflammationf
Plasma CRP concentration ≥10 mg/L 5.0% (? 5.1% to 16.1%) 0.34 ?
Plasma AGP concentration ≥1.0 g/L 14.0% (? 1.5% to 27.9%) 0.03 ?
Plasma CRP concentration ≥10 mg/L, or AGP ≥1.0 g/L 6.6% (? 3.1% to 17.2%) 0.19 ?
AGP, α1-acid glycoprotein; CRP, C-reactive protein; sTfR, Soluble transferrin receptor; ZPP, Zinc protoporphyrin.
aZPP values were normalised by log transformation; exponentiation of results yielded associations being expressed as percentage differences; bThe table shows
only results for factors that were independently associated with whole blood ZPP and erythrocyte ZPP; because these final (parsimonious) models were obtained
with backward elimination procedures, this resulted in different sets of factors being included for whole blood ZPP and erythrocyte ZPP; cDifference; dPlasma
ferritin concentration <15 μg/L; eEither HRP2- or pLDH-based dipstick; fPlasma concentrations of CRP >10 mg/L and/or AGP >1 g/L.
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http://www.biomedcentral.com/1741-7015/12/229areas should receive universal iron supplementation; in-
stead, children should be screened and supplementation
should be restricted to those with iron deficiency [23].
Unfortunately, however, there are no simple, rapid tests
available to implement this recommendation under field
conditions. The WHO has pointed to the need to validateZPP in malaria-endemic areas [23]. We believe that this
lack of validity applies equally to pregnant women and
children.
Iron status is commonly monitored by haemoglobin
concentration, haematocrit, and plasma ferritin concentra-
tion [4]. Whereas cut-off points for these markers have
Table 3 Factors associated with ZPP (μmol/mol haem) measured in erythrocytesa
Univariate analysis Multivariate analysisb
Δc (95% CI) P Δc (95% CI) P
Gravidity 0.13
Primigravida [Reference] ?
Secundigravida 23.4% ( ? 4.3% to 59.2%) ?
Multigravida 23.2% (0.0% to 51.7%) ?
Gestational age 0.48
13? 14 weeks [Reference] ?
15? 16 weeks ? 4.6% ( ? 29.4% to 29.0%) ?
16? 18 weeks 13.9% ( ? 15.3% to 53.2%) ?
19? 21 weeks 6.1% ( ? 21.6% to 43.8%) ?
22? 25 weeks ? 5.0% ( ? 33.1% to 34.8%) ?
Anaemia 94.6% ( ? 67.5% to 126.2%) <0.001 46.3% (26.9% to 68.8%) <0.001
Iron deficiencyd 87.6% ( ? 62.1% to 117.1%) <0.001 41.0% (21.5% to 63.5%) <0.001
Plasma sTfR concentration, mg/L 48.3% ( ? 40.0% to 57.1%) <0.001 34.2% (25.6% to 43.3%) <0.001
Plasma transferrin concentration, g/L 85.3% ( ? 63.2% to 110.4%) <0.001 15.6% (0.9% to 32.5%) 0.04
Plasma folate concentration, μg/L 0.6% ( ? 1.8% to 2.9%) 0.64 24.0% (3.0% to 49.3%) 0.02
Plasma vitamin B12 concentration, 100pmol/L ? 3.5% ( ? 6.4% to ? 0.7%) 0.02 ?
Plasma total bilirubin concentration, μmol/L ? 3.0% ( ? 4.8% to ? 1.1%) 0.002 ? 2.2% ( ? 3.7% to ? 0.7%) 0.005
Plasma LDH concentration, 10 IU/L ? 0.4% ( ? 1.2% to 0.3%) 0.21 ? 0.1% ( ? 0.2% to 0.0%) 0.003
α+-thalassaemia genotype 0.87
Normal [Reference] ?
Heterozygote ? 5.9% ( ? 25.2% to 18.3%) ?
Homozygote ? 4.7% ( ? 37.9% to 46.2%) ?
Plasmodium infection
Any Plasmodium spp., by any dipstick or PCR ? 3.0% ( ? 17.5% to 14.1%) 0.71 ?
Current or recent P. falciparum infectione ? 10.2% ( ? 26.3% to 9.5%) 0.29 ?
P. falciparum, by dipstick,e or PCR ? 3.0% ( ? 17.5% to 14.1%) 0.71 ?
P. falciparum, by PCR ? 1.4% ( ? 16.3% to 16.3%) 0.87 ?
HIV infection ? 8.5% ( ? 24.6% to 11.0%) 0.37 ?
Plasma CRP concentration, mg/L ? 0.1% ( ? 0.6% to 0.5%) 0.82 ?
Plasma AGP concentration, g/L 1.4% ( ? 24.0% to 35.2%) 0.92 ?
Inflammationf
Plasma CRP concentration ≥10 mg/L ? 2.1% ( ? 18.0% to 16.8%) 0.81 ?
Plasma AGP concentration ≥1.0 g/L 3.2% ( ? 15.8% to 26.5%) 0.76 ?
Plasma CRP concentration ≥10 mg/L, or AGP ≥1.0 g/L ? 4.2% ( ? 19.0% to 13.2%) 0.61 ?
AGP, α1-acid glycoprotein; CRP, C-reactive protein; sTfR, Soluble transferrin receptor; ZPP, Zinc protoporphyrin.
aZPP values were normalised by log transformation; exponentiation of results yielded associations being expressed as percentage differences; bThe table shows
only results for factors that were independently associated with whole blood ZPP and erythrocyte ZPP; because these final (parsimonious) models were obtained
with backward elimination procedures, this resulted in different sets of factors being included for whole blood ZPP and erythrocyte ZPP; cDifference; dPlasma
ferritin concentration <15 μg/L; eEither HRP2- or pLDH-based dipstick; fPlasma concentrations of CRP >10 mg/L and/or AGP >1 g/L.
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unreliable in pregnancy because these markers are affec-
ted by plasma expansion. By contrast, ZPP content can be
expressed as a molar ratio to haem, which should theo-
retically be independent of haemodilution. Thus, ZPP has
been proposed as a preferred marker for iron status inpregnancy [3]. Furthermore, erythrocyte ZPP was reported
to be a sensitive and specific indicator in the detection of
iron deficiency in non-pregnant women and young chil-
dren aged 1 to 5 years in the USA and in areas where the
prevalence of elevated blood lead concentration is not
high [25].
Figure 1 (See legend on next page.)
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Figure 1 Ability of erythrocyte protoporphyrin, either alone or combined with haemoglobin concentration, to discriminate between
pregnant women with and without iron deficiency. (Panel A) Receiver operating characteristics (ROC) curve for various blood markers, used
alone, to discriminate between iron-deficient and iron-replete women. Area-under-the-curve (AUC; 95% CI): whole blood ZPP: (0.66; 0.57? 0.74);
erythrocyte ZPP: (0.73; 0.65? 0.80); EP: (0.59; 0.50? 0.68); haemoglobin concentration: (0.61; 0.52? 0.70). (Panel B) Cumulative relative frequency
distribution of erythrocyte ZPP, the best indicator when used as a single test (Panel A) to discriminate between iron-deficient and iron-replete
women. The black circle in Panel A and the dotted black line in Panel B indicate the erythrocyte ZPP:haem ratio of 34 μmol/mol whereby the
total diagnostic error is minimised at a prevalence of iron deficiency of 50%. (Panels C, E, and G) ROC curves for whole blood ZPP, erythrocyte
ZPP, and EP, either alone or each in combination with haemoglobin concentration. AUC; 95% CI: combined whole blood ZPP with haemoglobin
concentration: (0.64; 0.56? 0.73); combined erythrocyte ZPP with haemoglobin concentration: (0.72; 0.64? 0.80); combined EP with haemoglobin
concentration: (0.64; 0.55? 0.73). (Panel D) Bivariate scatterplot for whole blood ZPP and haemoglobin concentration, by iron status; (Panel F)
Bivariate scatterplot for erythrocyte ZPP and haemoglobin concentration, by iron status; (Panel H) Bivariate scatterplot for EP and haemoglobin
concentration, by iron status. Grey dashed lines in ROC curves indicate a ?worst? possible test, which has no discriminatory value and an
area-under-the-curve (AUC) of 0.5. An ideal marker would have a curve that runs from the lower-left via the upper-left to the upper-right corner,
yielding an AUC of 1.0.
Table 4 Diagnostic performance of ZPP, measured in whole blood or erythrocytes, in detecting iron deficiencya at
hypothetical prevalence values (50%, 30%, and 10%) for iron deficiencyb
Cut-point Sensitivity Specificity True prevalence PPV NPV Estimated prevalence
Whole blood ZPP, μmol/mol haem
>70c 78% 47% 50% 59% 68% 66%
30% 39% 83% 61%
10% 14% 95% 56%
>49d 95% 3.2% 50% 50% 39% 96%
30% 30% 60% 96%
10% 10% 85% 97%
>85e 63% 63% 50% 63% 63% 50%
>102e 43% 76% 30% 43% 76% 30%
>160e 13% 90% 10% 13% 90% 10%
Erythrocyte ZPP, μmol/mol haem
>70f 38% 87% 50% 75% 58% 26%
30% 56% 77% 21%
10% 25% 93% 16%
>40g 64% 68% 50% 66% 65% 48%
30% 46% 81% 42%
10% 18% 94% 35%
>11h 95% 19% 50% 54% 80% 88%
30% 34% 90% 85%
10% 12% 97% 82%
>34i 67% 67% 50% 67% 67% 50%
>52i 48% 77% 30% 48% 77% 30%
>81i 27% 92% 10% 27% 92% 10%
PPV, Positive predictive value; NA, Not applicable; NPV, Negative predictive value.
aDefined as serum ferritin concentration <15 μg/L; bAnalysis restricted to women without inflammation, Plasmodium infection or HIV infection; cCut-off point
corresponding to 2.7 μg/g, which has been selected to define the presence of iron-deficient erythropoiesis [23]; dCut-off point selected for screening, with a
sensitivity of 95%; eCut-off points selected to yield unbiased estimates of the prevalence of iron deficiency (see text); fRecommended range to indicate iron deficiency in
the absence of infection [24]; gCut-off point recommended to distinguish between iron deficient erythropoiesis and iron sufficient erythropoiesis [2]; hCut-off point
selected for screening, with a sensitivity of 95%; iCut-off points selected to yield unbiased estimates of the prevalence of iron deficiency (see text).
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http://www.biomedcentral.com/1741-7015/12/229A strong point in our study was that we measured
ZPP both in whole blood and in washed erythrocytes.
We strictly adhered to protocol, conducted measure-
ments in duplicate, and ran control samples as per in-
structions by the manufacturer. Lead exposure in our
study population was probably very low. We ensured
comprehensive assessment of iron status in all the par-
ticipants using different markers as recommended by
various guidelines [2,26]. The iron markers, inflamma-
tion markers, and haemolysis markers reported in this
study, as well as EP concentrations, were assessed inde-
pendently by laboratories that were not involved in the
fieldwork. In addition, by using a broad array of methods
(dipsticks, PCR, and histopathology), we probably de-
tected most asymptomatic Plasmodium infections. The
high acceptance of HIV testing (98%) enabled us to
study the diagnostic performance of ZPP in the presence
of HIV as a chronic infection.
We found no strong, consistent evidence that indi-
cators of haemolysis (bilirubin, lactate dehydrogenase),
infection (Plasmodium, HIV), or inflammation were as-
sociated with ZPP. An explanation may be that our study
subjects probably had high levels of acquired protective
immunity against malaria, whilst effects of HIV infec-
tion may have been suppressed by the use of antiretro-
viral therapy.
Although fewer than 1% of women had low plasma
concentrations of folate (<3 μg/L) and vitamin B12
(<150 pmol/L), these findings should be interpreted
with caution, because these plasma markers reflect both
intake and stores, and are subject to large inter-laboratory
and inter-assay variability [27].
When analysing the diagnostic performance of ZPP,
we based our definition of iron deficiency on plasma fer-
ritin concentration, whilst restricting our dataset to wo-
men without inflammation, Plasmodium infection, or
HIV infection. Plasma ferritin concentration reacts as an
acute phase protein and can be elevated in the presence
of infection-induced inflammation independently of iron
status. It can be argued that, as an alternative, the ratio
of concentrations of soluble transferrin receptor/log fer-
ritin can be used in an unrestricted dataset. This ratio,
however, is a marker of body iron content and we found
its use to define iron deficiency problematic: it will be
influenced by inflammation because serum ferritin con-
centration is one component of the ratio [2]. It will also
be influenced by Plasmodium infection independent of
iron status, since serum transferrin receptor concentra-
tions also reflect increased erythropoiesis induced by
Plasmodium infection [28,29]. Additional arguments
against the use of this ratio in this paper are provided in
its pre-publication history (available online).
Plasma ferritin concentration with an adjusted cut-off
value (e.g., 30 μg/L) has been advocated to define irondeficiency in the presence of inflammation. Implicitly,
however, this definition assumes that the effect of in-
flammation on plasma ferritin concentration is identical
for all individuals within a population or across popula-
tions, whereas in reality, this will depend on many fac-
tors including the degree and duration of inflammation,
as well as immunity and its proxy indicators (e.g., age).
Particularly in a population with Plasmodium infection,
there is currently no marker or combination of markers
to accurately diagnose iron deficiency.
Our study had several limitations. First, for practical
reasons, we could not assess the α+-thalassaemia status
of all participants. However, we found no associations
between ZPP and α+-thalassaemia in the women in whom
α+-thalassaemia genotype was established. Secondly, we
studied pregnant women. Although we do not expect that
the diagnostic performance of ZPP is better in children,
we cannot exclude this possibility. In addition, other con-
ditions and genetic disorders such as sickle cell anaemia
and G6PD, which may influence the diagnostic utility of
ZPP, were not studied.
Several other studies also found that detection of
iron deficiency by ZPP leads to marked overestimates
of the prevalence of iron deficiency [6,7,30,31]. For ex-
ample, in Kenyan children, this prevalence was 80% for
ZPP >80 μmol/mol haem versus 41% for ferritin con-
centration <12 μg/L (after correction for inflammation)
[6]. In Tanzanian children without Plasmodium infec-
tion, corresponding values were 56% versus 40% [7].
These discrepancies may have been due at least in part
to inflammation or infection [2,24]. Several studies
have shown that ZPP content in whole blood can be
markedly higher than values measured in washed erythro-
cytes. Various reasons, including interference by bilirubin,
have been cited [8,20,32-34]. Our findings show, however,
that this overestimation is also in large part due to low
specificity to ZPP at conventionally used cut-off points,
whether measured in whole blood or in erythrocytes. Se-
lection of cut-points for dichotomized diagnostic tests
should depend on the diagnostic aims. When used as an
initial screening marker to manage iron deficiency, ZPP
should be highly sensitive, with a view to rule out iron de-
ficiency (i.e., a high negative predictive value, no longer
needing work-up) or to identify individuals who are iron
deficient or who need further diagnostic work-up. Our
findings show, however, that a high sensitivity will inevit-
ably be accompanied by a low specificity, and thus an un-
acceptably low negative predictive value. For example, in
Table 4, we have shown that for whole blood ZPP, a sen-
sitivity of 95% can be obtained with a cut-off point of
49 μmol/mol haem. However, the corresponding speci-
ficity is 3.5%, resulting in negative predictive values that
will be unacceptably low with true prevalence values
for iron deficiency in most conditions. As an exception,
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http://www.biomedcentral.com/1741-7015/12/229erythrocyte ZPP may have limited value to rule out iron
deficiency in populations with low prevalence of iron
deficiency (Table 4). These results were obtained in a
restricted dataset, with exclusion of women with inflam-
mation, Plasmodium infection, or HIV infection. The
diagnostic performance of ZPP in an unrestricted data-
set would presumably have been even worse.
When applied to estimate the prevalence of iron defi-
ciency, ZPP cut-off points can be calibrated to produce
estimates that are not biased by diagnostic error.
Conclusions
In this population, both whole blood ZPP and erythrocyte
ZPP have little diagnostic utility as a screening marker to
manage iron deficiency, whether used as single tests or
combined with haemoglobin concentration. When used to
estimate the prevalence of iron deficiency, conventional
cut-off points for whole blood ZPP can result in marked
overestimates. Based on these findings, guidelines on the
use of ZPP to assess iron status in individuals or popula-
tions of pregnant women need review.
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